AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10369612
Drug: Fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 20 mg tablet
Trial: 10369612
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of fosinopril 20 mg plus HCTZ 12.5 mg
Trial: 10369612
Drug: Coadministered tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministered tablets of fosinopril 20 mg and HCTZ 12.5 mg
Trial: 6148621
Drug: Cimetidine (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400-800 mg/day)
Trial: 24549963
Drug: 200-mg imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg imatinib tablet
Trial: 24549963
Drug: 2×100-mg imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×100-mg imatinib tablets
Trial: 22371023
Drug: fs-laser therapy
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fs-laser therapy (simulated with modified contact lenses)
Trial: 18391051
Drug: Standard cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioral treatment (CBT)
Trial: 18391051
Drug: Brief cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive-behavioral treatment (CBT)
Trial: 10069782
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine (L‐methionine 100 mg/kg)
Trial: 10069782
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine preceded by vitamin C (1g/day, for 1 week)
Trial: 2149673
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of etodolac
Trial: 2149673
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg of etodolac
Trial: 6130557
Drug: Destyrosine-gamma-endorphin (DTGE)
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Destyrosine-gamma-endorphin (DTGE) high doses (20-120 mg)
Trial: 23313532
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus manual therapy
Trial: 23313532
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus exercise therapy
Trial: 23313532
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus combined exercise therapy and manual therapy
Trial: 22108471
Drug: Viatromb (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viatromb (heparin spraygel 2.400 IU/g)
Trial: 19728560
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Trial: 19728560
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Trial: 11496446
Drug: Brief couple
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief couple therapy intervention (2 to 4 sessions)
Trial: 8038871
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training combined with phosphatidylserine 2 x 200 mg/day
Trial: 8038871
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training combined with pyritinol 2 x 600 mg/day
Trial: 8038871
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training twice a week
Trial: 1206472
Drug: high-justification-pill
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-justification-pill
Trial: 1206472
Drug: no-justification-pill
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-justification-pill
Trial: 1206472
Drug: high-justification-no-pill
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-justification-no-pill
Trial: 1206472
Drug: no-pill-no-justification
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-pill-no-justification
Trial: 30673996
Drug: Spiritual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiritual therapy (12 sessions, 60 minutes each, twice a week)
Trial: 26468453
Drug: Selenomethionine (SLM)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (SLM) 3600 μg/m(2) twice daily for 7 days prior to CRT, once daily during CRT, and daily for 3 weeks following CRT
Trial: 23554139
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (PFMT and PFMT + TrA)
Trial: 18646366
Drug: Clear gel
RxNorm normalized name: Tucks Clear Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear gel negative control toothpaste
Trial: 17441971
Drug: Topiramate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (mean modal dose ± SD = 100 ± 17 mg/day)
Trial: 15479128
Drug: Leptin concentration
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin concentration in subcutaneous fat tissue
Trial: 15479128
Drug: TNFalpha concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFalpha concentration in subcutaneous fat tissue
Trial: 11398153
Drug: Ciprofibrate 100
RxNorm normalized name: ciprofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 100 mg/d
Trial: 11398153
Drug: Gemfibrozil 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1,200 mg/d
Trial: 7836516
Drug: Fertility drugs
RxNorm normalized name: Tests for fertility disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fertility drugs
Trial: 7836516
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fertility drugs)
Trial: 3400659
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment for 2 years
Trial: 11966951
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 2 years
Trial: 28643425
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U100 (IGlar)
Trial: 20511192
Drug: CED of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CED of cintredekin besudotox (CB) at 0.5 microg/mL administered over 96 hours via 2-4 intraparenchymal catheters after tumor resection
Trial: 20511192
Drug: Gliadel wafers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliadel wafers (GW) at 3.85%/7.7 mg carmustine per wafer, maximum 8 wafers placed immediately after tumor resection
Trial: 18455389
Drug: Protein ingestion
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein ingestion (15 g whey)
Trial: 11837570
Drug: Antibacterial eradication
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial eradication therapy
Trial: 10613232
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Ultrasound gel and Vaseline)
Trial: 8573412
Drug: Alendronate 20
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 20 mg/day
Trial: 8573412
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin 100 IU/day
Trial: 1902992
Drug: Cefotaxime and
RxNorm normalized name: cefotaxime and beta-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime and Clindamycin (CC)
Trial: 1902992
Drug: Both AGC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both AGC and CC
Trial: 6771815
Drug: 0.85 g
RxNorm normalized name: MENTHOL 0.85 g in 17 g TOPICAL PATCH [SINSINPAS COLD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g alcohol/kg body weight
Trial: 6771815
Drug: 0.63 g
RxNorm normalized name: phytosterol/om-3/dha/epa/fish 0.63 gram-232.5 mg-92.5 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.63 g alcohol/kg body weight
Trial: 6771815
Drug: 0.41 g
RxNorm normalized name: PETROLATUM 0.41 g in 1 g TOPICAL OINTMENT [Equate Baby Advanced Healing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.41 g alcohol/kg body weight
Trial: 28157725
Drug: Person-Centered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-Centered Therapy (PCT)
Trial: 23981368
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions over 3 months)
Trial: 23981368
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no placebo treatment)
Trial: 17635487
Drug: Antimicrobial vaginal
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial vaginal pessary containing tetracycline and amphotericin B, administered twice a day for 14 days after LLETZ
Trial: 16013901
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (fluoxetine [N = 42] and paroxetine [N = 43])
Trial: 12542933
Drug: Patient medication
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient medication diaries
Trial: 7648717
Drug: IgM-enriched IVIG
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched IVIG (250 mg/kg per day for 4 days)
Trial: 7648717
Drug: Standard IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IVIG (250 mg/kg per day for 4 days)
Trial: 7648717
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no IVIG, supportive and antibiotic therapy)
Trial: 2667612
Drug: Topical 1
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1 alpha,25-dihydroxyvitamin D3 (0.5 microgram applied twice daily)
Trial: 345313
Drug: Oral pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pimozide
Trial: 345313
Drug: Depot injections
RxNorm normalized name: methylprednisolone Injection [Depo-Medrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot injections of fluphenazine decanoate
Trial: 31303099
Drug: Ultrafiltration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration therapy
Trial: 27546708
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin therapy
Trial: 28003302
Drug: Conservative Treatment
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Treatment
Trial: 25216771
Drug: Umezu polyphenols
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umezu polyphenols (UP) 800 mg daily for 12 weeks
Trial: 25216771
Drug: Placebo 0
RxNorm normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg daily for 12 weeks
Trial: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1200 mg m(‐2) on days 1, 8 and 15 every 28 days
Trial: 15266334
Drug: Paclitaxel (PTX)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PTX) 100 mg m(‐2) on days 1, 8 and 15 every 28 days
Trial: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg m(‐2) plus Paclitaxel (PTX) 80 mg m(‐2) (GT) on days 1 and 8 every 21 days
Trial: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg m(‐2) plus Vinorelbine (VNR) 25 mg m(‐2) (GV) on days 1 and 8 every 21 days
Trial: 11555525
Drug: Placebo CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo CPAP treatment
Trial: 9928578
Drug: Dose-escalating CEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalating CEF
Trial: 9928578
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of CEF followed by high-dose chemotherapy and autologous stem cell support
Trial: 9928578
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy for 2 years
Trial: 28077338
Drug: 10-day B-quadruple
RxNorm normalized name: amphotericin B 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)
Trial: 28077338
Drug: 10-day omeprazole-based
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily)
Trial: 28077338
Drug: B-quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-quadruple therapy
Trial: 25640470
Drug: Omalizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (750 mg monthly)
Trial: 23661521
Drug: Olanzapine (2.5‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5‐15 mg)
Trial: 23661521
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Valproate (600‐1000 mg)
Trial: 18285565
Drug: High-dose myoblasts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose myoblasts
Trial: 18285565
Drug: Myoblasts (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoblasts (combined treatment)
Trial: 8559495
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs (ditazole, ticlopidine, aspirin plus dipyridamole)
Trial: 8559495
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet drugs
Trial: 8559495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (uraemic patients not on rHuEpo therapy)
Trial: 7419011
Drug: Intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fat (20 g of Intralipid)
Trial: 7419011
Drug: Intraduodenal fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal fat (20 g of Intralipid)
Trial: 7419011
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids (21 g L‐amino acids; Freamine II) plus glucose (50 g)
Trial: 30776476
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1800 mg containing 1206 mg EPA) for 12 weeks
Trial: 30640652
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of perineural dexamethasone
Trial: 30640652
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of perineural dexamethasone
Trial: 30640652
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of perineural dexamethasone
Trial: 23524017
Drug: Supratherapeutic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals)
Trial: 23524017
Drug: Supratherapeutic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic doses of ipratropium bromide (IPR) 20 μg, 20 μg, and 40 μg (at 20 min intervals)
Trial: 23524017
Drug: Supratherapeutic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals) after MABA 1200
Trial: 23524017
Drug: Supratherapeutic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic doses of ipratropium bromide (IPR) after MABA 1200
Trial: 19515536
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release MET (500 to 1000 mg daily)
Trial: 11499332
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine 250 mg once daily for 2 or 4 weeks
Trial: 8159103
Drug: Dilevalol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 400 mg x 1
Trial: 8159103
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 200 mg x 1
Trial: 29343998
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure therapy
Trial: 29689045
Drug: Parenting group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenting group intervention (visits by child development agents and fortnightly meetings)
Trial: 26755466
Drug: Cognitive-existential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-existential group therapy (12 sessions of 90 minutes twice per week)
Trial: 22584916
Drug: CD4-guided planned
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD4-guided planned treatment interruptions (PTIs)
Trial: 21358200
Drug: Finafloxacin 200
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin 200 mg
Trial: 21358200
Drug: Finafloxacin 800
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin 800 mg
Trial: 8833554
Drug: PCA morphine:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine: 1 mg with 6-minute lockout
Trial: 8833554
Drug: PCACI: PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCACI: PCA morphine 1 mg with 6-minute lockout plus 0.5-1 mg/h continuous infusion
Trial: 1558438
Drug: Theophylline treatment
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline treatment (oral, 7 days, plasma level 87.7 +/‐ 7.8 mumol/L)
Trial: 25141137
Drug: 10-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Trial: 25141137
Drug: 14-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Trial: 25141137
Drug: 10-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Trial: 25141137
Drug: 10-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Trial: 25141137
Drug: 14-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Trial: 25141137
Drug: 14-day levofloxacin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Trial: 11788212
Drug: Intravenous followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous followed by oral conjugated estrogen for 21 days
Trial: 11788212
Drug: Intravenous estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days
Trial: 2111627
Drug: Nalbuphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (10 mg)
Trial: 27466224
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL Hyaluronic Acid (HA) injection
Trial: 27466224
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL saline solution (placebo)
Trial: 17044900
Drug: Oral baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral baclofen
Trial: 10545429
Drug: Accelerated alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated alteplase (100 mg/90 min; n=21)